Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $6.34 per share which beat the analyst consensus estimate of $4.57 by 38.73 percent. This is a 277.38 percent increase over earnings of $1.68 per share from the same period last year. The company reported quarterly sales of $1.609 billion which beat the analyst consensus estimate of $976.563 million by 64.76 percent. This is a 79.21 percent increase over sales of $897.841 million the same period last year.